Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Summary

Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.

Conditions

• Cervical Cancer

Interventions

DRUG

Cadonilimab

The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment

Sponsors & Collaborators

• Fujian Medical University Affiliated Nanping First Hospital

  collaborator UNKNOWN

• The First Hospital Affiliated to Fujian Medical University

  collaborator UNKNOWN

• Fujian Medical University Union Hospital

  collaborator OTHER

• Gutian Hospital

  collaborator UNKNOWN

• Jiangxi Provincial Cancer Hospital

  collaborator OTHER

• Shunde Women and Children's Hospital (Maternity and Child Healthcare Hospital of Shunde Foshan)

  collaborator UNKNOWN

• Lianyungang Donghai County People's Hospital

  collaborator UNKNOWN

• Changsha Maternal and Child Health Hospital

  collaborator UNKNOWN

• Pingxiang Maternal and Child Health Hospital

  collaborator UNKNOWN

• Huinan County People's Hospital

  collaborator UNKNOWN

• People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

  collaborator UNKNOWN

• Fujian Cancer Hospital

  lead OTHER_GOV

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-09-07

Primary Completion

2024-12-31

Completion

2026-12-31

Countries

• China

Study Locations